CMPX
NASDAQ HealthcareCompass Therapeutics, Inc. - Common Stock
Biotechnology
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $1.96 |
|---|---|
| Volume | 10,369,749 |
| Market Cap | 352.97M |
| Beta | 1.300 |
| RSI (14-Day) | 26.0 Oversold |
| 200-Day MA | $4.61 |
| 50-Day MA | $5.12 |
| 52-Week High | $6.88 |
| 52-Week Low | $1.61 |
| Forward P/E | -4.82 |
| Price / Book | 1.78 |
๐ฏ Investment Strategy Scores
CMPX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CMPX in your text
Paste any article, transcript, or post โ the tool will extract CMPX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.